October 24, 2007 – During a live demonstration at TCT 2007 of CoreValve’s 18-French ReValving System for percutaneous aortic valve replacement (PAVR), cardiologists performed the implantation of the device in a high-risk patient suffering from Chronic Obstructive Pulmonary Disease (COPD).
CoreValve’s third-generation aortic heart valve was implanted successfully and non-surgically in a patient suffering from COPD, using its percutaneous, 18-French ReValving System. Eberhard Grube, M.D., and Ulrich Gerckens, M.D., of the HELIOS Heart Center, Siegburg, Germany, performed the revalving procedure live via satellite television from their hospital’s cath lab for an audience comprised of cardiologists, cardiovascular surgeons and industry executives.
“This was the 158th revalving procedure within the scope of our post-CE Mark Expanded Evaluation registry. When combined with the results of 191 previous cases of the feasibility, safety and efficacy trials, it demonstrates that interventional cardiology treatment of structural heart disease is no longer just a hope for the future but a reality today that provides a new treatment option for high-risk and inoperable patients,” said Jacques Séguin, M.D., Ph.D., Chairman, CEO and Founder of CoreValve.
For more information: www.corevalve.com
April 17, 2024 
